{"links": [{"source": 0, "target": "t8573", "value": "None"}, {"source": 0, "target": "t8563", "value": "None"}, {"source": "t8573", "target": "t8574", "value": "None"}, {"source": "t8563", "target": "t8572", "value": "None"}, {"source": "t8563", "target": "t8571", "value": "None"}, {"source": "t8563", "target": "t8564", "value": "None"}, {"source": "t8574", "target": "t8576", "value": "None"}, {"source": "t8574", "target": "t8575", "value": "None"}, {"source": "t8564", "target": "t8565", "value": "None"}, {"source": "t8576", "target": "t8577", "value": "None"}, {"source": "t8576", "target": "t8575", "value": "None"}, {"source": "t8576", "target": "d98", "value": "None"}, {"source": "t8576", "target": "d71", "value": "None"}, {"source": "t8576", "target": "d31", "value": "None"}, {"source": "t8576", "target": "d174", "value": "None"}, {"source": "t8575", "target": "t8577", "value": "None"}, {"source": "t8575", "target": "t8576", "value": "None"}, {"source": "t8565", "target": "t8566", "value": "None"}, {"source": "t8577", "target": "t8578", "value": "None"}, {"source": "t8566", "target": "t8567", "value": "None"}, {"source": "t8566", "target": "t8568", "value": "None"}, {"source": "t8578", "target": "t8579", "value": "None"}, {"source": "t8568", "target": "t8569", "value": "None"}, {"source": "t8569", "target": "t8570", "value": "None"}, {"source": "t8570", "target": "t8568", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Pulmonary_fibrosis", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Pulmonary_fibrosis"}}, {"category": "treatment", "id": "t8573", "name": "adult with idiopathic pulmonary fibrosis", "draggable": "true", "value": {"name": "adult with idiopathic pulmonary fibrosis", "type": "treatment related", "time": "", "intention": "", "description": "title:adult with idiopathic pulmonary fibrosis", "drug": {}}}, {"category": "treatment", "id": "t8563", "name": "adult with possible clinical features of idiopathic pulmonary fibrosis", "draggable": "true", "value": {"name": "adult with possible clinical features of idiopathic pulmonary fibrosis", "type": "treatment related", "time": "", "intention": "", "description": "title:adult with possible clinical features of idiopathic pulmonary fibrosis", "drug": {}}}, {"category": "treatment", "id": "t8574", "name": "assess for pulmonary rehabilitation programme tailored for idiopathic pulmonary fibrosis", "draggable": "true", "value": {"name": "assess for pulmonary rehabilitation programme tailored for idiopathic pulmonary fibrosis", "type": "treatment related", "time": "", "intention": "", "description": "title:assess for pulmonary rehabilitation programme tailored for idiopathic pulmonary fibrosishead:Assess for pulmonary rehabilitation programme tailored for idiopathic pulmonary fibrosisAssess people with idiopathic pulmonary fibrosis for pulmonary rehabilitation at the time of diagnosis. Assessment may include a 6-minute walk test (distance walked and oxygen saturation measured by pulse oximetry) and a quality-of-life assessment. Repeat the assessment for pulmonary rehabilitation for people with idiopathic pulmonary fibrosis at 6-month or 12-month intervals. If appropriate after each assessment, offer pulmonary rehabilitation including exercise and educational components tailored to the needs of people with idiopathic pulmonary fibrosis in general. Pulmonary rehabilitation should be tailored to the individual needs of each person with idiopathic pulmonary fibrosis. Sessions should be held somewhere that is easy for people with idiopathic pulmonary fibrosis to get to and has good access for people with disabilities.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.4Pulmonary rehabilitationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8572", "name": "patient experience in adult nhs services", "draggable": "true", "value": {"name": "patient experience in adult nhs services", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience in adult nhs services", "drug": {}}}, {"category": "treatment", "id": "t8571", "name": "respiratory conditions", "draggable": "true", "value": {"name": "respiratory conditions", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:respiratory conditions", "drug": {}}}, {"category": "treatment", "id": "t8564", "name": "be aware of clinical features of idiopathic pulmonary fibrosis", "draggable": "true", "value": {"name": "be aware of clinical features of idiopathic pulmonary fibrosis", "type": "treatment related", "time": "", "intention": "", "description": "title:be aware of clinical features of idiopathic pulmonary fibrosishead:Be aware of clinical features of idiopathic pulmonary fibrosisBe aware of idiopathic pulmonary fibrosis when assessing a patient with the clinical features listed below and when considering requesting a chest X-ray or referring to a specialist: age over 45 years persistent breathlessness on exertion  persistent cough bilateral inspiratory crackles when listening to the chest clubbing of the fingers normal spirometry or impaired spirometry usually with a restrictive pattern but sometimes with an obstructive pattern.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8576", "name": "offer drugs to treat idiopathic pulmonary fibrosis and withdraw ineffective therapies", "draggable": "true", "value": {"name": "offer drugs to treat idiopathic pulmonary fibrosis and withdraw ineffective therapies", "type": "treatment related", "time": "", "intention": "bosentan\nbosentan is used to treat pulmonary arterial hypertension (pah) in adults and children who are at least 3 years old. it improves your ability to exercise and prevents your condition from getting worse.\nbosentan may also be used for purposes not listed in this medication guide.", "description": "title:offer drugs to treat idiopathic pulmonary fibrosis and withdraw ineffective therapieshead:Offer drugs to treat idiopathic pulmonary fibrosis and withdraw ineffective therapiesThere is no conclusive evidence to support the use of any drugs to increase the survival of people with idiopathic pulmonary fibrosis. subhead:NintedanibThe following recommendations are from NICE technology appraisal guidance on nintedanib for treating idiopathic pulmonary fibrosis.Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if: the person has a forced vital capacity (FVC) between 50% and 80% of predicted  the company provides nintedanib with the discount agreed in the patient access scheme and treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12-month period.People whose treatment with nintedanib is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.NICE has written information for the public explaining its guidance on nintedanib.subhead:PirfenidoneThe following recommendations are from NICE technology appraisal guidance on pirfenidone for treating idiopathic pulmonary fibrosis.Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis in adults only if: the person has a forced vital capacity (FVC) between 50% and 80% predicted the company provides pirfenidone with the discount agreed in the patient access scheme and treatment is stopped if there is evidence of disease progression (an absolute decline of 10% or more in predicted FVC within any 12-month period).This recommendation is not intended to affect treatment with pirfenidone that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.NICE has written information for the public explaining its guidance on pirfenidone.subhead:Other pharmacological treatmentsDo not use any of the drugs below, either alone or in combination, to modify disease progression in idiopathic pulmonary fibrosis:  ambrisentan azathioprine bosentan co-trimoxazole mycophenolate mofetil prednisolone sildenafil  warfarin. Advise the person that oral N-acetylcysteineAt the time of publication (June 2013), N-acetylcysteine did not have a UK marketing authorisation. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council s Good practice in prescribing medicines \u2013 guidance for doctors for further information.  is used for managing idiopathic pulmonary fibrosis, but its benefits are uncertain. If people with idiopathic pulmonary fibrosis are already using prednisolone or azathioprine, discuss the potential risks and benefits of discontinuing, continuing or altering therapy. Manage any comorbidities according to best practice. For gastro-oesophageal reflux disease, see NICE s recommendations on dyspepsia and gastro-oesophageal reflux disease.See what NICE says on medicines optimisation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163TA379TA504", "drug": {}}}, {"category": "treatment", "id": "t8575", "name": "offer best supportive care and symptom relief", "draggable": "true", "value": {"name": "offer best supportive care and symptom relief", "type": "treatment related", "time": "", "intention": "", "description": "title:offer best supportive care and symptom reliefhead:Offer best supportive care and symptom reliefOffer best supportive care to people with idiopathic pulmonary fibrosis from the point of diagnosis. Best supportive care should be tailored to disease severity, rate of progression, and the person s preference, and should include if appropriate: information and support (see offer information and support) symptom relief management of comorbidities withdrawal of therapies suspected to be ineffective or causing harm end of life care. Assess the oxygen needs of people who have been hospitalised with idiopathic pulmonary fibrosis before they are discharged. Ensure people with idiopathic pulmonary fibrosis, and their families and carers, have access to the full range of services offered by palliative care teams. Ensure there is collaboration between the healthcare professionals involved in the person s care, community services and the palliative care team. subhead:People breathless on exertionIf the person is breathless on exertion consider assessment for: the causes of breathlessness and degree of hypoxia and ambulatory oxygen therapy and long-term oxygen therapy and/or pulmonary rehabilitation. subhead:People breathless at restIf the person is breathless at rest consider: assessment for the causes of breathlessness and degree of hypoxia and assessment for additional ambulatory oxygen therapy and long-term oxygen therapy and the person s psychosocial needs and offering referral to relevant services such as palliative care services and pharmacological symptom relief with benzodiazepines and/or opioids. subhead:People with coughIf the person has a cough consider: treatment for causes other than idiopathic pulmonary fibrosis (such as gastro-oesophageal reflux disease, post-nasal drip) treating with opioids if the cough is debilitating discussing treatment with thalidomideAt the time of publication (June 2013), thalidomide did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council s Good practice in prescribing medicines \u2013 guidance for doctors for further information. with a consultant respiratory physician with expertise in interstitial lung disease if the cough is intractable.See what NICE says on opioids for pain relief in palliative care.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.3Assessment for oxygen therapy5Palliative careSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8565", "name": "take a detailed medical history", "draggable": "true", "value": {"name": "take a detailed medical history", "type": "treatment related", "time": "", "intention": "", "description": "title:take a detailed medical historyhead:Take a detailed medical historyAssess everyone with suspected idiopathic pulmonary fibrosis by:  taking a detailed history, carrying out a clinical examination (see be aware of clinical features of idiopathic pulmonary fibrosis) and performing blood tests to help exclude alternative diagnoses, including lung diseases associated with environmental and occupational exposure, with connective tissue diseases and with drugs. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8577", "name": "explore lung transplantation", "draggable": "true", "value": {"name": "explore lung transplantation", "type": "treatment related", "time": "", "intention": "", "description": "title:explore lung transplantationhead:Explore lung transplantationRefer people with idiopathic pulmonary fibrosis for lung transplantation assessment if they  wish to explore lung transplantation and if there are no absolute contraindications. (See discussing lung transplantation in offer information and support.) Ask the transplant centre for an initial response within 4 weeks. NICE has published interventional procedures guidance on living donor lung transplantation for end-stage lung disease.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8566", "name": "perform clinical investigations", "draggable": "true", "value": {"name": "perform clinical investigations", "type": "treatment related", "time": "", "intention": "", "description": "title:perform clinical investigationshead:Perform clinical investigationsAssess everyone with suspected idiopathic pulmonary fibrosis by:  performing lung function testing (spirometry and gas transfer) and reviewing results of chest X-ray and performing CT of the thorax (including high-resolution images). Diagnose idiopathic pulmonary fibrosis only with the consensus of the multidisciplinary team, based on: the clinical features, lung function and radiological findings pathology when indicated. subhead:If a confident diagnosis cannot be madeIf the multidisciplinary team cannot make a confident diagnosis from clinical features, lung function and radiological findings, consider:  bronchoalveolar lavage or transbronchial biopsy and/or surgical lung biopsy, with the agreement of the thoracic surgeon.Discuss with the person who may have idiopathic pulmonary fibrosis: the potential benefits of having a confident diagnosis compared with the uncertainty of not having a confident diagnosis and the increased likelihood of obtaining a confident diagnosis with surgical biopsy compared with bronchoalveolar lavage or transbronchial biopsy and the increased risks of surgical biopsy compared with bronchoalveolar lavage or transbronchial biopsy. When considering bronchoalveolar lavage, transbronchial biopsy or surgical lung biopsy take into account:  the likely differential diagnoses and the person s clinical condition, including any comorbidities. If a confident diagnosis cannot be made continue to review the person under specialist care.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Diagnosis of idiopathic pulmonary fibrosisSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8578", "name": "review and follow up", "draggable": "true", "value": {"name": "review and follow up", "type": "treatment related", "time": "", "intention": "", "description": "title:review and follow-uphead:Review and follow-upIn follow-up appointments for people with idiopathic pulmonary fibrosis: assess lung function assess for oxygen therapy assess for pulmonary rehabilitation offer smoking cessation advice, in line with NICE s recommendations on smoking identify exacerbations and previous respiratory hospital admissions consider referral for assessment for lung transplantation in people who do not have absolute contraindications (see explore lung transplantation) consider psychosocial needs and referral to relevant services as appropriate consider referral to palliative care services assess for comorbidities (which may include anxiety, bronchiectasis, depression, diabetes, dyspepsia, ischaemic heart disease, lung cancer and pulmonary hypertension). Consider follow-up of people with idiopathic pulmonary fibrosis: every 3 months or sooner if they are showing rapid disease progression or rapid deterioration of symptoms or  every 6 months or sooner if they have steadily progressing disease or  initially every 6 months if they have stable disease and then annually if they have stable disease after 1 year. For information about reducing the risk of death and ill health associated with living in a cold home, see NICE s recommendations on excess winter deaths and illnesses associated with cold homes.See what NICE says on multimorbidity.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Assessment for oxygen therapySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8567", "name": "role of the multidisciplinary team in diagnosis", "draggable": "true", "value": {"name": "role of the multidisciplinary team in diagnosis", "type": "treatment related", "time": "", "intention": "", "description": "title:role of the multidisciplinary team in diagnosishead:Role of the multidisciplinary team in diagnosisAt each stage of the diagnostic care pathway the multidisciplinary team should consist of a minimum of the healthcare professionals listed in table 1, all of whom should have expertise in interstitial lung disease. See chapter 6.5 (Multidisciplinary Team) in the full guideline for more information on the expertise of the multidisciplinary team. subhead:Table 1 Minimum composition of multidisciplinary team involved in diagnosing idiopathic pulmonary fibrosisStage of diagnostic care pathway Multidisciplinary team composition (all healthcare professionals should have expertise in interstitial lung disease)After clinical evaluation, baseline lung function and CT  Consultant respiratory physician  Consultant radiologist  Interstitial lung disease specialist nurse  Multidisciplinary team coordinator When considering performing bronchoalveolar lavage, and/or transbronchial biopsy or surgical lung biopsyOnly some patients will have bronchoalveolar lavage or transbronchial biopsy but they may be being considered for surgical lung biopsy  Consultant respiratory physician  Consultant radiologist  Consultant histopathologist  Thoracic surgeon as appropriate  Interstitial lung disease specialist nurse  Multidisciplinary team coordinator When considering results of bronchoalveolar lavage, transbronchial biopsy or surgical lung biopsy  Consultant respiratory physician  Consultant radiologist  Consultant histopathologist  Interstitial lung disease specialist nurse  Multidisciplinary team coordinator Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Diagnosis of idiopathic pulmonary fibrosisSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8568", "name": "offer information and support", "draggable": "true", "value": {"name": "offer information and support", "type": "treatment related", "time": "", "intention": "", "description": "title:offer information and supporthead:Offer information and supportThe consultant respiratory physician or interstitial lung disease specialist nurse should provide accurate and clear information (verbal and written) to people with idiopathic pulmonary fibrosis, and their families and carers with the person s consent. This should include information about investigations, diagnosis and management. NICE has produced guidance on the components of good patient experience in adult NHS services. Follow NICE s recommendations on patient experience. An interstitial lung disease specialist nurse should be available at all stages of the care pathway to provide information and support to people with idiopathic pulmonary fibrosis and their families and carers with the person s consent. Offer advice, support and treatment to aid smoking cessation to all people with idiopathic pulmonary fibrosis who also smoke, in line with NICE s recommendations on stop smoking interventions and services. subhead:Discussing lung transplantationDiscuss lung transplantation as a treatment option for people with idiopathic pulmonary fibrosis who do not have absolute contraindications. Discussions should:  take place between 3 and 6 months after diagnosis or sooner if clinically indicated be supported by an interstitial lung disease specialist nurse include the risks and benefits of lung transplantation  involve the person s family and carers with the person s consent.(See offer best supportive care and symptom relief.) subhead:Discussing ventilationA respiratory physician or specialist nurse with an interest in interstitial lung disease should discuss the poor outcomes associated with mechanical ventilation (including non-invasive mechanical ventilation) for respiratory failure with people with idiopathic pulmonary fibrosis. These discussions should ideally take place between 3 to 6 months after diagnosis or sooner if clinically indicated. (See offer best supportive care and symptom relief.)Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.2Access to a specialist nurseSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8579", "name": "care at the end of life", "draggable": "true", "value": {"name": "care at the end of life", "type": "treatment related", "time": "", "intention": "", "description": "title:care at the end of lifehead:Care at the end of lifeDo not routinely offer mechanical ventilation (including non-invasive mechanical ventilation) to people with idiopathic pulmonary fibrosis who develop life-threatening respiratory failure. (See discussing ventilation in offer information and support.)See also what NICE says on end of life care for people with life-limiting conditions.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8569", "name": "assess prognosis", "draggable": "true", "value": {"name": "assess prognosis", "type": "treatment related", "time": "", "intention": "", "description": "title:assess prognosishead:Assess prognosisMeasure the initial rate of decline in the person s condition, which may predict subsequent prognosis, by using lung function test results (spirometry and gas transfer) at: diagnosis and  6 months and 12 months after diagnosis. Repeat the lung function tests at shorter intervals if there is concern that the person s condition is deteriorating rapidly. Discuss prognosis with people with idiopathic pulmonary fibrosis in a sensitive manner and include information on: the severity of the person s disease and average life expectancy the varying courses of disease and range of survival  management options available.Do not use the 6-minute walk distance at diagnosis to estimate prognosis. (The 6-minute walk test may be useful for other purposes, see assess for pulmonary rehabilitation programme tailored for idiopathic pulmonary fibrosis.) SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG163", "drug": {}}}, {"category": "treatment", "id": "t8570", "name": "managing idiopathic pulmonary fibrosis", "draggable": "true", "value": {"name": "managing idiopathic pulmonary fibrosis", "type": "treatment related", "time": "", "intention": "", "description": "title:managing idiopathic pulmonary fibrosis", "drug": {}}}, {"category": "drug", "id": "d98", "name": "bosentan", "draggable": "true", "value": {"name": "bosentan", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d71", "name": "azathioprine", "draggable": "true", "value": {"name": "azathioprine", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d31", "name": "ambrisentan", "draggable": "true", "value": {"name": "ambrisentan", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d174", "name": "co-trimoxazole", "draggable": "true", "value": {"name": "co-trimoxazole", "time": "None", "period": "None", "dosage": "None"}}]}